Summary

This article discusses the nomenclature of neuroendocrine tumors (NETs), according to the updated 2010 World Health Organization (WHO) classification. This scheme classifies NETs based on prognostication by their proliferative activities, with respect to mitotic rate and Ki-67 labeling index. Since this accounts for tumor grading and prognosis, it facilitates development of treatment strategies, with somatostatin receptor 2a-positive tumors in particular demonstrating improved response to therapy with somatostatin analogs.